The trial, called CALAVI, will assess the effect of Calquence on the exaggerated immune response of patients hospitalised with COVID-19 infection (PRESS RELEASE) CAMBRIDGE, 14-Apr-2020 — /EuropaWire/ — Pharmaceutical giant AstraZeneca to begin a randomised, global clinical trial to assess … Read the full press release
Posted in Healthcare, Science, Sweden, Technology, United Kingdom
Tagged assisted ventilation, AstraZeneca, best supportive care, blood cancers, Bruton’s tyrosine kinase, BSC, BTK, BTK inhibitor, CALAVI, Calquence, clinical trial, COVID-19, cytokine storm, exaggerated immune response, inflammatory cytokines, José Baselga, Louis M. Staudt M.D. Ph.D., lung disease
European Commission approves Sandoz Rixathon® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare systems to reallocate resources to other healthcare priorities. Sandoz now has four biosimilars approved in Europe … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged blood cancers, European Commission, immunological diseases, MabThera®, Rixathon, Sandoz
NEWCASTLE, 9-6-2015 — /EuropaWire/ — A world-renowned blood cancers expert has been given a prestigious award in recognition of his outstanding contribution in helping patients with the life-threatening conditions. Professor Graham Jackson, honorary clinical professor of clinical haematology at the Northern … Read the full press release
LEEDS, 20-5-2014 — /EuropaWire/ — A pioneering database at the University of Leeds will help match patients with certain types of blood cancers to the best treatments. The new resource, funded by the charity Leukaemia & Lymphoma Research, will store cancer … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
